Huntington's Disease Clinical Trials Corner: August 2018

Filipe B Rodrigues, Edward J Wild, Filipe B Rodrigues, Edward J Wild

Abstract

In the third edition of the Huntington's Disease Clinical Trials Corner we list all currently registered and ongoing clinical trials, expand on the SIGNAL trial (NCT02481674), and cover the recently finished CREST-E trial (NCT00712426).

Keywords: Huntington disease; clinical trials.

References

    1. Vaccinex Inc. Huntington Study Group. VX15/2503 Treatment for Huntington's Disease, 2015.
    1. Hersch SM, Schifitto G, Oakes D, Bredlau A-L, Meyers CM, Nahin R, et al. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology 2017;89(6):594–601.
    1. Massachusetts General Hospital. Creatine Safety. Tolerabil-ity, & Efficacy in Huntington's Disease (CREST-E), 2008.
    1. Rodrigues FB, Wild EJ Clinical Trials Corner: September 2017. J Huntingtons Dis 2017;6(3):255–63.
    1. Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, et al. Nonclinical Safety Evaluation of VX15/a Humanized IgG4 Anti-SEMA4D Antibody. Molecular cancer therapeutics 2015;14(4):964–72.
    1. Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease 2015;76, 46–56.
    1. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, et al. Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2016;22(4):827–36.
    1. LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, et al. Safety/tolerability of the anti-semaphorin 4D Antibody VX15/in a randomized phase 1 trial. Neurology® Neuroimmunology & Neuroinflammation. 2017;4(4):e367.
    1. Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, et al. PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82(10):850–7.
    1. Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport 2002;13(1):123–6.
    1. Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington’s disease. The Journal of International Medical Research 2008;36(5):896–905.
    1. Massachusetts General Hospital Creatine Safety and Tolerability in Premanifest HD: PRECREST 2008. .
    1. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 2006;66(2):250–2.
    1. National Center for Complementary and Integrative Health. Creatine Therapy for Huntington’s Disease, 2001.
    1. Rodrigues FB, Wild EJ Huntingtons Disease Clinical Trials Corner: February Journal of Huntington’s Disease 2018;7(1):89–98.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다